Two 483s Note Quality Problems at Indian Drug, API Manufacturing Plants

An Indian plant that makes a number of drugs and active pharmaceutical ingredients (API) was socked with a six-observation Form 483 noting multiple problems with validation testing for API and drug batches, as well as the validation tests themselves.
Source: Drug Industry Daily